Zacks Investment Research Downgrades Bionomics (NASDAQ:BNOX) to Hold

Zacks Investment Research cut shares of Bionomics (NASDAQ:BNOXGet Rating) from a buy rating to a hold rating in a research report report published on Friday morning, reports.

Shares of Bionomics stock traded down $0.89 during trading on Friday, hitting $7.56. 250 shares of the stock traded hands, compared to its average volume of 1,107. The business has a fifty day simple moving average of $8.55. Bionomics has a 52 week low of $5.70 and a 52 week high of $22.00.

An institutional investor recently bought a new position in Bionomics stock. Woodline Partners LP acquired a new stake in shares of Bionomics Limited (NASDAQ:BNOXGet Rating) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 161,943 shares of the company’s stock, valued at approximately $2,032,000. Woodline Partners LP owned about 2.89% of Bionomics at the end of the most recent quarter. Institutional investors and hedge funds own 7.86% of the company’s stock.

Bionomics Company Profile (Get Rating)

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder.

Featured Stories

Get a free copy of the Zacks research report on Bionomics (BNOX)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Bionomics (NASDAQ:BNOX)

Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with's FREE daily email newsletter.